Physician profile
Andrea E Cheneweth
NPI 1275548109
$9,847.87
in general payments reported to CMS, 2019-2025
48 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,281 · 2022: $2,782 · 2023: $1,861 · 2024: $1,593 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,765.65 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $835.45 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $814.82 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $754.49 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $595.03 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $593.26 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $579.91 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.54 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $363.89 | 2021-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $349.23 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $231.99 | 2021-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $218.57 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $215.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.73 | 2021-2023 | |
| Abbott Laboratories | $191.41 | 2022-2025 | Freestyle Libre |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Cheneweth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.